Compare Stocks: UTHR, REGN, ARGX, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$865.04	$879.13	$631.47 ▼ $953.58	$54.12B	0.46	282,694 shs	250,017 shs
REGN Regeneron Pharmaceuticals	$784.36	$657.28	$541.00 ▼ $821.11	$80.76B	0.21	794,515 shs	837,569 shs
RVMD Revolution Medicines	$205.15	$176.66	$34.14 ▼ $205.90	$43.97B	1.39	1.87 million shs	1.67 million shs
UTHR United Therapeutics	$538.84	$539.43	$292.34 ▼ $609.35	$23.11B	0.59	506,284 shs	1.20 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+1.31%	-1.43%	+6.36%	+30.70%
REGN Regeneron Pharmaceuticals	0.00%	+2.85%	+18.03%	+10.04%	+39.32%
RVMD Revolution Medicines	0.00%	+9.40%	+9.78%	+42.32%	+486.14%
UTHR United Therapeutics	0.00%	+4.08%	-1.50%	-5.45%	+78.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$865.04	$879.13	$631.47 ▼ $953.58	$54.12B	0.46	282,694 shs	250,017 shs
REGN Regeneron Pharmaceuticals	$784.36	$657.28	$541.00 ▼ $821.11	$80.76B	0.21	794,515 shs	837,569 shs
RVMD Revolution Medicines	$205.15	$176.66	$34.14 ▼ $205.90	$43.97B	1.39	1.87 million shs	1.67 million shs
UTHR United Therapeutics	$538.84	$539.43	$292.34 ▼ $609.35	$23.11B	0.59	506,284 shs	1.20 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+1.31%	-1.43%	+6.36%	+30.70%
REGN Regeneron Pharmaceuticals	0.00%	+2.85%	+18.03%	+10.04%	+39.32%
RVMD Revolution Medicines	0.00%	+9.40%	+9.78%	+42.32%	+486.14%
UTHR United Therapeutics	0.00%	+4.08%	-1.50%	-5.45%	+78.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	22.18% Upside
REGN Regeneron Pharmaceuticals	2.67	Moderate Buy	$797.75	1.71% Upside
RVMD Revolution Medicines	2.95	Moderate Buy	$153.05	-25.39% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	19.89% Upside

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	RVMD Revolution Medicines	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$192.10 ➝ $201.00
8/6/2026	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$230.00
8/6/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$515.00
8/6/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$182.00 ➝ $203.00
8/6/2026	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$235.00 ➝ $240.00
8/6/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$236.00 ➝ $240.00
8/6/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$704.00 ➝ $677.00
8/4/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1,185.00
8/3/2026	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$700.00 ➝ $740.00
8/3/2026	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,000.00 ➝ $1,030.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.74	$21.33 per share	40.55	$118.34 per share	7.31
REGN Regeneron Pharmaceuticals	$14.34B	5.63	$41.97 per share	18.69	$295.66 per share	2.65
RVMD Revolution Medicines	$11.58M	3,797.22	N/A	N/A	$8.44 per share	24.31
UTHR United Therapeutics	$3.18B	7.26	$33.00 per share	16.33	$164.81 per share	3.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	33.22	24.18	1.09	32.19%	43.59%	36.66%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.39	15.52	1.33	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	N/A
UTHR United Therapeutics	$1.33B	$27.95	19.28	17.14	1.82	41.56%	20.18%	17.98%	N/A

Latest UTHR, REGN, ARGX, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.48%	N/A	9.29%	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest UTHR, REGN, ARGX, and RVMD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.51%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
RVMD Revolution Medicines	0.40	11.38	11.38
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
REGN Regeneron Pharmaceuticals	83.31%
RVMD Revolution Medicines	94.34%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
REGN Regeneron Pharmaceuticals	6.97%
RVMD Revolution Medicines	7.60%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

UTHR, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) EVP Sells $4,291,515.00 in Stock

August 9 at 5:45 AM | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,928,030.00 in Stock

August 9 at 5:45 AM | americanbankingnews.com

Royal Bank Of Canada Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $677.00

August 9 at 4:55 AM | americanbankingnews.com

Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR

August 9 at 3:35 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Sees Strong Trading Volume - Should You Buy?

August 7 at 11:39 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

August 7 at 6:37 AM | insidertrades.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,902,570.00 in Stock

August 7 at 4:43 AM | americanbankingnews.com

United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

August 7 at 3:20 AM | marketbeat.com

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

August 6, 2026 | finance.yahoo.com

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

August 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

August 6, 2026 | marketbeat.com

Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained

August 6, 2026 | tipranks.com

UTHR Q2 2026 deep dive: Product pipeline developments offset competitive pressures

August 6, 2026 | msn.com

Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

August 6, 2026 | marketbeat.com

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

August 6, 2026 | zacks.com

United Therapeutics Balances Tyvaso Woes With Pipeline Wins

August 5, 2026 | tipranks.com

United Therapeutics Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Announces Earnings Results

August 5, 2026 | marketbeat.com

United Therapeutics Q2 Net Income Rises, Revenue Falls

August 5, 2026 | finance.yahoo.com

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

August 5, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

$865.04 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$870.89 +5.85 (+0.68%)

As of 08:34 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals NASDAQ:REGN

$784.36 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$772.50 -11.86 (-1.51%)

As of 08:35 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Revolution Medicines NASDAQ:RVMD

$205.15 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$206.86 +1.72 (+0.84%)

As of 08:41 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

United Therapeutics NASDAQ:UTHR

$538.84 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$539.50 +0.66 (+0.12%)

As of 08:08 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, REGN, ARGX, and RVMD Earnings

Compare Dividends

Latest UTHR, REGN, ARGX, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Regeneron Pharmaceuticals NASDAQ:REGN

Revolution Medicines NASDAQ:RVMD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, REGN, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, REGN, ARGX, and RVMD Earnings

Compare Dividends

Latest UTHR, REGN, ARGX, and RVMD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, REGN, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR, REGN, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Regeneron Pharmaceuticals NASDAQ:REGN

Revolution Medicines NASDAQ:RVMD

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools